The deal will see the Singapore-based social technology company list on the Nasdaq, valuing the combined entity at approximately $300 million.
The marketing application for AVT23, a biosimilar to the multi-billion dollar asthma drug Xolair, marks a key regulatory step for Alvotech in the European market.
First patients implanted with the novel neurostimulator marks a key step in challenging market leader Inspire Medical after recent FDA approval.
The designation for ALTO-101 targets cognitive impairment, a debilitating condition with no currently approved treatments, signaling a major regulatory milestone.
Predictive Discovery and Robex Resources merge, creating a mid-tier producer targeting over 400,000 ounces of gold annually.
Conditional approval for Dectomax-CA1 addresses a significant threat to the U.S. livestock industry, boosting company shares.
Strategic acquisition aims to bolster Firefly's national security and defense capabilities, expanding its space and defense mission services.
Early results for ARV-102, a novel PROTAC LRRK2 degrader, show the experimental therapy is well-tolerated and demonstrates key biomarker engagement.